SEARCH

SEARCH BY CITATION

References

  • 1
    Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M. and Chen, L., Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 2007. 7: 95106.
  • 2
    Funakoshi, S., Longo, D. L., Beckwith, M., Conley, D. K., Tsarfaty, G., Tsarfaty, I., Armitage, R. J. et al., Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994. 83: 27872794.
  • 3
    Pellat-Deceunynck, C., Amiot, M., Robillard, N., Wijdenes, J. and Bataille, R., CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res. 1996. 56: 19091916.
  • 4
    Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C. et al., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005. 65: 10891096.
  • 5
    Advani, R. H., Furman, R. R., Rosenblatt, J. D., Younes, A., Forero-Torres, A., Harrop, K. L., Baumgartner, K. T. et al., A Phase I Study of Humanized Anti-CD40 Immunotherapy with SGN-40 in Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 2005. 106: Abstract 5150.
  • 6
    Hussein, M. A., Berenson, J. R., Niesvizky, R., Munshi, N. C., Harrop, K. L., McDonald, M. and Drachman, J. G., A Phase I Humanized Anti-CD40 Monoclonal Antibody (SGN-40) in Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2005. 106: Abstract 2572.
  • 7
    Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P. et al., Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 2007. 25: 876883.
  • 8
    Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T. et al., Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 2003. 100: 47124717.
  • 9
    Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M. et al., Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005. 23: 60436053.
  • 10
    Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P. et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 2003. 100: 83728377.
  • 11
    Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E. et al., Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 2005. 28: 593598.
  • 12
    Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B. et al., Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 2005. 23: 89688977.
  • 13
    Miller, R. E., Jones, J., Le, T., Whitmore, J., Boiani, N., Gliniak, B. and Lynch, D. H., 4-1BB-specific monoclonal antibody promotes the generation of tumor- specific immune responses by direct activation of CD8 T cells in a CD40- dependent manner. J. Immunol. 2002. 169: 17921800.
  • 14
    Zhu, Y., Zhu, G., Luo, L., Flies, A. S., Chen, L., CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 2007. 109: 48824889.
  • 15
    Lee, S. W., Park, Y., Song, A., Cheroutre, H., Kwon, B. S. and Croft, M., Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J. Immunol. 2006. 177: 44644472.
  • 16
    Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J. et al., 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 1997. 186: 4755.
  • 17
    Kim, Y. J., Kim, S. H., Mantel, P. and Kwon, B. S., Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur. J. Immunol. 1998. 28: 881890.
  • 18
    Kocak, E., Lute, K., Chang, X., May, K. F., Jr., Exten, K. R., Zhang, H., Abdessalam, S. F. et al., Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 2006. 66: 72767284.
  • 19
    Leach, D. R., Krummel, M. F. and Allison, J. P., Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996. 271: 17341736.
  • 20
    Shimizu, J., Yamazaki, S. and Sakaguchi, S., Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999. 163: 52115218.
  • 21
    Weinberg, A. D., Rivera, M. M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J. et al., Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 2000. 164: 21602169.
  • 22
    Curtsinger, J. M., Lins, D. C. and Mescher, M. F., Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 2003. 197: 11411151.
  • 23
    Kurts, C., Sutherland, R. M., Davey, G., Li, M., Lew, A. M., Blanas, E., Carbone, F. R. et al., CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 1999. 96: 1270312707.
  • 24
    Miller, J. F., Heath, W. R., Allison, J., Morahan, G., Hoffmann, M., Kurts, C. and Kosaka, H., T cell tolerance and autoimmunity. Ciba Found. Symp. 1997. 204: 159168; discussion 168–171.
  • 25
    Kurts, C., Heath, W. R., Carbone, F. R., Allison, J., Miller, J. F. and Kosaka, H., Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 1996. 184: 923930.
  • 26
    Kurts, C., Carbone, F. R., Barnden, M., Blanas, E., Allison, J., Heath, W. R. and Miller, J. F., CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J. Exp. Med. 1997. 186: 20572062.
  • 27
    Hamilton-Williams, E. E., Lang, A., Benke, D., Davey, G. M., Wiesmuller, K. H. and Kurts, C., Cutting edge: TLR ligands are not sufficient to break cross-tolerance to self-antigens. J. Immunol. 2005. 174: 11591163.
  • 28
    Bloom, M. B., Perry-Lalley, D., Robbins, P. F., Li, Y., el-Gamil, M., Rosenberg, S. A. and Yang, J. C., Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 1997. 185: 453459.
  • 29
    Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E. et al., Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 2002. 109: 651659.
  • 30
    Takahashi, C., Mittler, R. S. and Vella, A. T., Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 1999. 162: 50375040.
  • 31
    Taraban, V. Y., Rowley, T. F., O'Brien, L., Chan, H. T., Haswell, L. E., Green, M. H., Tutt, A. L. et al., Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. 2002. 32: 36173627.
  • 32
    Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellstrom, K. E., Mittler, R. S. and Chen, L., Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 1997. 3: 682685.
  • 33
    Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S. and Chen, L., NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 1998. 190: 167172.
  • 34
    Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002. 3: 991998.
  • 35
    Jones, E., Dahm-Vicker, M., Simon, A. K., Green, A., Powrie, F., Cerundolo, V. and Gallimore, A., Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002. 2: 112.
  • 36
    Golgher, D., Jones, E., Powrie, F., Elliott, T. and Gallimore, A., Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 2002. 32: 32673275.
  • 37
    Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999. 59: 31283133.
  • 38
    Zhang, B., Maris, C. H., Foell, J., Whitmire, J., Niu, L., Song, J., Kwon, B. S. et al., Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J. Clin. Invest. 2007. 117: 30293041.
  • 39
    Lee, S. J., Myers, L., Muralimohan, G., Dai, J., Qiao, Y., Li, Z., Mittler, R. S. and Vella, A. T., 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J. Immunol. 2004. 173: 30023012.
  • 40
    Steinaa, L., Rasmussen, P. B., Wegener, A. M., Sonderbye, L., Leach, D. R., Rygaard, J., Mouritsen, S. and Gautam, A. M., Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth. J. Immunol. 2005. 175: 329334.
  • 41
    Bansal-Pakala, P., Halteman, B. S., Cheng, M. H. and Croft, M., Costimulation of CD8 T cell responses by OX40. J. Immunol. 2004. 172: 48214825.
  • 42
    Lee, H. W., Park, S. J., Choi, B. K., Kim, H. H., Nam, K. O. and Kwon, B. S., 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J. Immunol. 2002. 169: 48824888.
  • 43
    Saoulli, K., Lee, S. Y., Cannons, J. L., Yeh, W. C., Santana, A., Goldstein, M. D., Bangia, N. et al., CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 1998. 187: 18491862.
  • 44
    Weinberg, A. D., Evans, D. E., Thalhofer, C., Shi, T. and Prell, R. A., The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J. Leukoc. Biol. 2004. 75: 962972.
  • 45
    Arch, R. H. and Thompson, C. B., 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol. Cell. Biol. 1998. 18: 558565.
  • 46
    Futagawa, T., Akiba, H., Kodama, T., Takeda, K., Hosoda, Y., Yagita, H. and Okumura, K., Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 2002. 14: 275286.
  • 47
    Croft, M., Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 2003. 14: 265273.
  • 48
    Zheng, G., Wang, B. and Chen, A., The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J. Immunol. 2004. 173: 24282434.
  • 49
    Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D. and Colombo, M. P., Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005. 105: 28452851.
  • 50
    Lee, J., Lee, E. N., Kim, E. Y., Park, H. J., Chang, C. Y., Jung, D. Y., Choi, S. Y. et al., Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol. Lett. 2005. 101: 210216.
  • 51
    George, A. J, McBride, H. M., Glennie, M. J., Smith, L. J. and Stevenson, F. K., Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants. Hybridoma 1991. 10: 219227.
  • 52
    Hasbold, J., Johnson-Leger, C., Atkins, C. J., Clark, E. A. and Klaus, G. G., Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies. Eur. J. Immunol. 1994. 24: 18351842.